Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Papamichail

Showing results (41-50 of 66) with videos related to

Pageof 7
Sort By:
Cancer|February 27, 2010
A new era in anticancer peptide vaccinesSonia A Perez, Eric von Hofe, Nikoletta L Kallinteris, et al.
Cancer Immunology, Immunotherapy : CII|September 19, 2003
Natural CD8+ T-cell responses against MHC class I epitopes of the HER-2/ neu oncoprotein in patients with epithelial tumorsPanagiota A Sotiropoulou, Sonia A Perez, Volfgang Voelter, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|June 15, 2005
Transcoronary transplantation of autologous mesenchymal stem cells and endothelial progenitors into infarcted human myocardiumDemosthenes G Katritsis, Panagiota A Sotiropoulou, Evangelia Karvouni, et al.
Cancer Immunology, Immunotherapy : CII|June 11, 2005
Immunogenic HER-2/neu peptides as tumor vaccinesConstantin N Baxevanis, Nectaria N Sotiriadou, Angelos D Gritzapis, et al.
Biochimica Et Biophysica Acta|August 30, 2005
A HER-2/neu peptide admixed with PLA microspheres induces a Th1-biased immune response in miceKonstantina N Nikou, Nikolaos Stivaktakis, Konstantinos Avgoustakis, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 21, 2008
Identification of a novel immunogenic HLA-A*0201-binding epitope of HER-2/neu with potent antitumor propertiesAngelos D Gritzapis, Ioannis F Voutsas, Eftychia Lekka, et al.
Cancer Immunology, Immunotherapy : CII|June 1, 2015
A pilot study in prostate cancer patients treated with the AE37 Ii-key-HER-2/neu polypeptide vaccine suggests that HLA-A*24 and HLA-DRB1*11 alleles may be prognostic and predictive biomarkers for clinical benefitEleftheria A Anastasopoulou, Ioannis F Voutsas, Theodora Keramitsoglou, et al.
Cancer Immunology, Immunotherapy : CII|August 13, 2010
A phase I trial of adoptive transfer of allogeneic natural killer cells in patients with advanced non-small cell lung cancerEleni G Iliopoulou, Panteleimon Kountourakis, Michalis V Karamouzis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 6, 2006
Increased frequency of CD4+ cells expressing CD161 in cancer patientsEleni G Iliopoulou, Michalis V Karamouzis, Ioannis Missitzis, et al.
Journal of Immunological Methods|September 7, 2002
A skeletal muscle troponin T specific ELISA based on the use of an antibody against the soluble troponin T (16-31) fragmentOurania E Tsitsilonis, Stanka Stoeva, Hartmut Echner, et al.
Pageof 7

Showing results (41-50 of 66) with videos related to

Sort By:
Pageof 7
Cancer|February 27, 2010
A new era in anticancer peptide vaccinesSonia A Perez, Eric von Hofe, Nikoletta L Kallinteris, et al.
Cancer Immunology, Immunotherapy : CII|September 19, 2003
Natural CD8+ T-cell responses against MHC class I epitopes of the HER-2/ neu oncoprotein in patients with epithelial tumorsPanagiota A Sotiropoulou, Sonia A Perez, Volfgang Voelter, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|June 15, 2005
Transcoronary transplantation of autologous mesenchymal stem cells and endothelial progenitors into infarcted human myocardiumDemosthenes G Katritsis, Panagiota A Sotiropoulou, Evangelia Karvouni, et al.
Cancer Immunology, Immunotherapy : CII|June 11, 2005
Immunogenic HER-2/neu peptides as tumor vaccinesConstantin N Baxevanis, Nectaria N Sotiriadou, Angelos D Gritzapis, et al.
Biochimica Et Biophysica Acta|August 30, 2005
A HER-2/neu peptide admixed with PLA microspheres induces a Th1-biased immune response in miceKonstantina N Nikou, Nikolaos Stivaktakis, Konstantinos Avgoustakis, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 21, 2008
Identification of a novel immunogenic HLA-A*0201-binding epitope of HER-2/neu with potent antitumor propertiesAngelos D Gritzapis, Ioannis F Voutsas, Eftychia Lekka, et al.
Cancer Immunology, Immunotherapy : CII|June 1, 2015
A pilot study in prostate cancer patients treated with the AE37 Ii-key-HER-2/neu polypeptide vaccine suggests that HLA-A*24 and HLA-DRB1*11 alleles may be prognostic and predictive biomarkers for clinical benefitEleftheria A Anastasopoulou, Ioannis F Voutsas, Theodora Keramitsoglou, et al.
Cancer Immunology, Immunotherapy : CII|August 13, 2010
A phase I trial of adoptive transfer of allogeneic natural killer cells in patients with advanced non-small cell lung cancerEleni G Iliopoulou, Panteleimon Kountourakis, Michalis V Karamouzis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 6, 2006
Increased frequency of CD4+ cells expressing CD161 in cancer patientsEleni G Iliopoulou, Michalis V Karamouzis, Ioannis Missitzis, et al.
Journal of Immunological Methods|September 7, 2002
A skeletal muscle troponin T specific ELISA based on the use of an antibody against the soluble troponin T (16-31) fragmentOurania E Tsitsilonis, Stanka Stoeva, Hartmut Echner, et al.
Pageof 7